Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Lancet Infectious Diseases
Sep 2019 Volume 19Number 9p915-1034, e301-e336
http://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial
Kayvon Modjarrad, et al